More recent results demonstrated that shRNA-mediated silencing of BMI-1 also sensitizes myeloma cells to bortezomib, which was attributed to increased expression of p21 and BCL2-associated X protein (Bax) [20]. This evidence concerns the gene BAX and plasma cell myeloma.